332 related articles for article (PubMed ID: 17873693)
1. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
2. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
3. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Bushe C; Shaw M
J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
[TBL] [Abstract][Full Text] [Related]
5. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
6. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
[TBL] [Abstract][Full Text] [Related]
9. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
10. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Kopecek M; Bares M; Horacek J; Mohr P
Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
[TBL] [Abstract][Full Text] [Related]
11. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
[TBL] [Abstract][Full Text] [Related]
12. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
13. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
14. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
15. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients.
Ohta C; Yasui-Furukori N; Furukori H; Tsuchimine S; Saito M; Nakagami T; Yoshizawa K; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):573-6. PubMed ID: 21216266
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Bai YM; Chen TT; Lin WK; Chang WH; Wu B; Hung CH; Chou P; Chen JY
J Clin Psychopharmacol; 2007 Jun; 27(3):306-8. PubMed ID: 17502783
[No Abstract] [Full Text] [Related]
17. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
Kinon BJ; Gilmore JA; Liu H; Halbreich UM
Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
[TBL] [Abstract][Full Text] [Related]
18. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics.
Bonete Llácer JM; Martínez Hortelano A; Richart Albelda B
Int J Psychiatry Clin Pract; 2019 Sep; 23(3):189-193. PubMed ID: 30848967
[No Abstract] [Full Text] [Related]
20. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
